checkAd

     113  0 Kommentare Virogentics, Inc. Receives Permit for Export to Africa of the ITV-1 Immunotherapy Solidifying the Scheduled Administration of the Treatment

    Reports on Business combination agreement progress

    ALLEN, TX / ACCESSWIRE / August 8, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).

    Virogentics, Inc. ("VIRO") a wholly owned subsidiary of Enzolytics, Inc. (the "Company" or "ENZC"), a drug development biotech company, announced today the receipt of an export permit for the delivery of the treatments to be administered to the volunteer HIV/AIDS patients at the HEAL Africa Hospitals, GOMA, PRC and Panzi Hospital, Bukavu, DRC. The results of this African pilot clinical trial will be used in the development of the European Medicine Authority (EMA) clinical trials expected to begin in late 2023/early 2024.

    Additionally, VIRO acknowledges the announcement by Sagaliam Acquisition Corp, ("NASDAQ:SAGA") that they had notified Continental Stock and Transfer Company that it was exercising the option to extend the time available to consummate a business combination agreement by an additional month to August 23, 2023. VIRO reports that substantial progress has been made on the combination agreement.

    Barry Kostiner, the CEO of Sagaliam, stated "The VIRO team has done a great job of moving forward on their clinical and regulatory milestones. We are getting involved at the right time to provide the resources needed to build a platform for helping many people in Africa, Europe and globally."

    Harry Zhabilov, Chief Scientific Officer of VIRO, stated "Every day we move closer to the ultimate goal of administering our immunotherapy to patients who we believe will benefit greatly from our technology, as well as the funding that will be unlocked by moving to NASDAQ."

    Enzolytics, Inc. Overview

    Enzolytics, Inc. is a drug development company committed to commercializing its proprietary proteins and monoclonal antibodies to treat debilitating infectious diseases. The Company is advancing multiple therapeutics targeting numerous infectious diseases. One patented and clinically tested compound, ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of Inactivated Pepsin Fraction (IPF), covered by U.S. Patent Nos. 8,066,982 and 7,479,538. Studies have shown it to be effective in treating HIV/AIDS. ITV-1 has also been shown to modulate the immune system.

    Seite 1 von 2


    Aktuelle Themen


    Accesswire
    0 Follower
    Autor folgen
    Mehr anzeigen
    We’re a newswire service standout and fast becoming an industry disruptor. We provide regional, national and global news to thousands of clients around the world. We’re also leading the way in social engagement, targeting and analytics.
    Mehr anzeigen

    Verfasst von Accesswire
    Virogentics, Inc. Receives Permit for Export to Africa of the ITV-1 Immunotherapy Solidifying the Scheduled Administration of the Treatment Reports on Business combination agreement progressALLEN, TX / ACCESSWIRE / August 8, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).Virogentics, Inc. ("VIRO") a wholly owned subsidiary of Enzolytics, Inc. (the "Company" or …